449 related articles for article (PubMed ID: 10864657)
21. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
[TBL] [Abstract][Full Text] [Related]
22. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
23. Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after
Phan SI; Adam CM; Chen Z; Citron M; Liang X; Espeseth AS; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747497
[TBL] [Abstract][Full Text] [Related]
24. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
27. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
28. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
29. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
Tang RS; Schickli JH; MacPhail M; Fernandes F; Bicha L; Spaete J; Fouchier RA; Osterhaus AD; Spaete R; Haller AA
J Virol; 2003 Oct; 77(20):10819-28. PubMed ID: 14512532
[TBL] [Abstract][Full Text] [Related]
30. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
Buchholz UJ; Granzow H; Schuldt K; Whitehead SS; Murphy BR; Collins PL
J Virol; 2000 Feb; 74(3):1187-99. PubMed ID: 10627529
[TBL] [Abstract][Full Text] [Related]
31. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.
Wiegand M; Gori-Savellini G; Martorelli B; Bossow S; Neubert WJ; Cusi MG
Vaccine; 2013 Aug; 31(37):3888-93. PubMed ID: 23831325
[TBL] [Abstract][Full Text] [Related]
33. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).
Stokes A; Tierney EL; Sarris CM; Murphy BR; Hall SL
Virus Res; 1993 Oct; 30(1):43-52. PubMed ID: 8266719
[TBL] [Abstract][Full Text] [Related]
34. The Fusion Protein Specificity of the Parainfluenza Virus Hemagglutinin-Neuraminidase Protein Is Not Solely Defined by the Primary Structure of Its Stalk Domain.
Tsurudome M; Ito M; Ohtsuka J; Hara K; Komada H; Nishio M; Nosaka T
J Virol; 2015 Dec; 89(24):12374-87. PubMed ID: 26423949
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
Stewart-Jones GBE; Chuang GY; Xu K; Zhou T; Acharya P; Tsybovsky Y; Ou L; Zhang B; Fernandez-Rodriguez B; Gilardi V; Silacci-Fregni C; Beltramello M; Baxa U; Druz A; Kong WP; Thomas PV; Yang Y; Foulds KE; Todd JP; Wei H; Salazar AM; Scorpio DG; Carragher B; Potter CS; Corti D; Mascola JR; Lanzavecchia A; Kwong PD
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12265-12270. PubMed ID: 30420505
[TBL] [Abstract][Full Text] [Related]
36. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
van Wyke Coelingh KL; Winter CC; Tierney EL; Hall SL; London WT; Kim HW; Chanock RM; Murphy BR
J Virol; 1990 Aug; 64(8):3833-43. PubMed ID: 1695256
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
[TBL] [Abstract][Full Text] [Related]
38. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
[TBL] [Abstract][Full Text] [Related]
39. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
[TBL] [Abstract][Full Text] [Related]
40. Alternative mechanisms of interaction between homotypic and heterotypic parainfluenza virus HN and F proteins.
Tong S; Compans RW
J Gen Virol; 1999 Jan; 80 ( Pt 1)():107-115. PubMed ID: 9934692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
